Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the r...

Full description

Saved in:

Bibliographic Details
Published in:	Emerging infectious diseases Vol. 27; no. 1; pp. 332 - 334
Main Authors:	Haley, Connie A, Macias, Patricia, Jasuja, Supriya, Jones, Betsy A, Rowlinson, Marie-Claire, Jaimon, Roshni, Onderko, Pennelyn, Darnall, Elaine, Gomez, Maria E, Peloquin, Charles, Ashkin, David, Goswami, Neela D
Format:	Journal Article
Language:	English
Published:	United States U.S. National Center for Infectious Diseases 01-01-2021 Centers for Disease Control and Prevention
Subjects:	antimicrobial resistance bedaquiline Biopsy Care and treatment Chemotherapy Diagnosis Disease control Dosage and administration Drug dosages drug monitoring Drug resistance Extensively drug-resistant tuberculosis FDA approval Infectious diseases Linezolid Medical laboratories Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States Patient outcomes Patients Pharmacy pretomanid Protein synthesis Public health Research Letter Tuberculosis tuberculosis and other mycobacteria United States Florida United States > US Illinois linezolid bacteria United States antimicrobial resistance BPaL Nix-TB drug monitoring tuberculosis and other mycobacteria pretomanid bedaquiline
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!